Clinical Trials

676 enrolled 15 charts

Infections, Papillomavirus Infections

NCT00956553 2020-10-01

HPV CSP01

Phase 4 Completed

400 enrolled

Papillomavirus Infections

NCT01031069 2020-07-21

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Phase 4 Completed

873 enrolled 34 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01381575 2020-06-09

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

1,447 enrolled 26 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01627561 2020-04-10

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

148 enrolled 28 charts

Papillomavirus Infections

NCT00586339 2020-01-03

Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females

150 enrolled 26 charts

Acquired Immunodeficiency Syndrome, Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00637195 2020-01-03

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

152 enrolled 21 charts

Uterine Cervical Neoplasms, Hepatitis B, Papillomavirus Infections

NCT00250276 2020-01-02

Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.

798 enrolled 19 charts

Papillomavirus Infections

NCT00294047 2020-01-02

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

5,752 enrolled 42 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00423046 2020-01-02

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

1,106 enrolled 27 charts

34,412 enrolled 21 charts

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00534638 2019-11-15

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

Phase 4 Completed

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01462357 2019-11-15

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

1,079 enrolled 26 charts

Papillomavirus Infections

NCT01249365 2019-11-13

The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

199 enrolled 9 charts

Papillomavirus Infections

NCT01190176 2019-10-30

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

34 enrolled 12 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01190189 2019-06-19

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

137 enrolled 9 charts

Papillomavirus Infections

NCT00309166 2018-09-17

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.

270 enrolled 14 charts

Papillomavirus Infections

NCT00492544 2018-09-04

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

100 enrolled 9 charts

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00122681 2018-08-20

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

18,729 enrolled 35 charts

Papillomavirus Infections

NCT00541970 2018-08-17

Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

Phase 1 Completed

961 enrolled 43 charts

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00578227 2018-08-17

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

814 enrolled 28 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01101542 2018-07-23

Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females

3,091 enrolled 19 charts

Papillomavirus Infections

NCT00344032 2018-07-20

Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women

354 enrolled 12 charts

Papillomavirus Infections

NCT00485732 2018-07-20

A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years

225 enrolled 14 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00549900 2018-07-20

A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females

Phase 1 Completed

30 enrolled 10 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00799825 2018-07-12

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

346 enrolled 8 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00546078 2018-06-26

Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America

116 enrolled 20 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00518336 2016-12-09

Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil

433 enrolled 66 charts

Papillomavirus Infections

NCT00811798 2016-10-20

Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.

92 enrolled 6 charts

Papillomavirus Infections

NCT00689741 2016-09-12

Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women

1,113 enrolled

Papillomavirus Infections

NCT02082639 2015-07-20

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years

Phase 3 Withdrawn

Papillomavirus Infections

NCT02100618 2015-07-20

Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study

Phase 3 Withdrawn

Papillomavirus Infections

NCT01498627 2015-04-06

PGRx

2,945 enrolled

Autoimmune Diseases, Papillomavirus Infections

NCT01187927 2015-01-26

Drug Use Investigation for Cervarix®

1,230 enrolled

Papillomavirus Infections

NCT01905462 2013-09-30

Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK

1,046 enrolled

Abortion, Spontaneous, Papillomavirus Infections

NCT00316706 2012-09-18

Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine

1,245 enrolled 11 charts